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Introduction 
 
 
 
1 Introduction 
In June 1981 the Morbidity and Mortality Weekly Report (MMWR), Centers for Disease 
Control and Prevention (CDC), carried a report of five cases of Pneumocystis carinii 
pneumonia (PCP) in homosexual men (1). The cause of this outbreak was unknown, but 
all five patients had evidence of cytomegalovirus (CMV) disease or virus shedding 
within five months of the diagnosis of PCP. In the accompanying editorial note, it was 
stated that the role of CMV in the pathogenesis of PCP was unknown. PCP is associated 
with immunodeficiency, and these were the first reported cases of acquired 
immunodeficiency syndrome (AIDS). The cause of AIDS was subsequently 
demonstrated to be a previously unknown virus – today known as human 
immunodeficiency virus (HIV). However, the interest in CMV in relation to HIV 
infection was not over, as it soon turned out that CMV was a cause of serious disease in 
coinfected individuals. CMV disease has remained an AIDS-defining disease since  
1981 (2). In addition, CMV was also early suspected of acting as a cofactor, inducing 
more rapid progression of HIV infection (3).  
During the late 1980s and mid-1990s, patients with AIDS occupied many beds in the 
wards at the Department of Infectious Diseases, Ullevål University Hospital. Death from 
complications of AIDS was frequent, and CMV disease was among the most dreaded 
complications. CMV retinitis lead to impaired vision and blindness, and CMV colitis 
caused severe diarrhoea. As a junior doctor, I first met AIDS patients with CMV disease 
in 1988. These troubled patients kindled my research interest in CMV and HIV 
coinfection. At the time, the autopsy rate in the hospital was high, over 70% in HIV-
related deaths, and this was an important asset in the study of CMV disease, which too 
often was diagnosed at the autopsy table. 
1.1 HIV  
It is generally acknowledged that Luc Montagnier and Françoise Barré-Sinoussi in 1983 
were the first to isolate the retrovirus known today as HIV (4;5). The following year 
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Robert Gallo provided more convincing evidence that HIV was indeed the cause of 
AIDS. Today, we know that there are two types of HIV, named HIV-1 and HIV-2. Both 
viruses probably originated in non-human primates in Africa, where they jumped the 
species barrier in the late 19th or early 20th century, having evolved from the closely 
related simian immunodeficiency virus (SIV) (6;7). HIV-2 is less virulent and most 
prevalent in West Africa. In this thesis, I will for the sake of simplicity refer to HIV-1 as 
HIV. 
HIV is a single-stranded ribonucleic acid (RNA) virus. As a retrovirus, HIV has the 
capacity to integrate into the host cell genome. It is dependent on several enzymes to 
convert RNA into deoxyribonucleic acid (DNA), and for subsequent integration into the 
host cell DNA. In the infected cells HIV may establish chronic infection with very high 
turnover, but may also lie dormant.  
HIV can infect CD4+ T cells, macrophages, dendritic cells and microglial cells. HIV 
specific CD4+ T cells carrying the CCR5 and CXCR4 chemokine coreceptors are 
preferentially targeted (8). Infection with HIV is usually followed by a quantitative 
decline in both CD4+ T cell count and function (9).  
In most HIV-infected individuals, HIV-specific CD4+ T cell mediated T helper function 
is relatively weak or absent (10). This abnormality in immune function is present at an 
early stage, before the loss of circulating CD4+ T cells that eventually is observed in 
most individuals. The preferential infection of HIV specific CD4+ T-cells provides a 
potential mechanism to explain the loss of HIV-specific CD4+ T-cell responses, which 
also contributes to the gradual loss of immunological control of HIV replication (8).  
1.2 CMV 
Human CMV is a double-stranded DNA virus that has several close relatives in animals. 
In this thesis, human CMV will for the sake of simplicity be referred to as CMV. CMV 
was first isolated in tissue culture in 1956 (11-13). Because the virus produced large, 
swollen, refractory cells, it was named cytomegalovirus, and it is also the largest known 
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human virus. CMV is a member of the herpesvirus group. The human herpesvirus group 
members comprise: 
x Alphaherpesviruses: Herpes simplex virus (HSV) 1 and 2, and varicella zoster 
virus (VZV) 
x Betaherpesviruses: CMV and Human herpes virus (HHV) 6 and 7 
x Gammaherpesviruses: Epstein-Barr virus (EBV) and Herpes virus 8  
These viruses all have in common the capacity to establish latent infection. Viral latency 
can be defined as the persistence of the viral genome in the absence of production of 
infectious virions, but with the ability of the viral genome to reactivate under specific 
stimuli (14). Clinical manifestations of CMV reactivation are uncommon in 
immunocompetent individuals, but can result in severe disease in patients with 
immunodeficiency. 
The CMV genome is highly conserved, but there is sufficient diversity to differentiate 
between several serotypes, mainly based on differences in the glycoprotein B constituent 
of the virion envelope. HIV-infected individuals are more frequently coinfected with 
different CMV strains than the general population (15).  
CMV infects many cell types, including polymorphonuclear leukocytes, monocytes, 
macrophages, T lymphocytes, endothelial vascular cells, renal epithelial cells, smooth 
muscle cells, neuronal cells, fibroblasts, and salivary glands (16). Epithelial cells, 
endothelial cells, fibroblasts and smooth muscle cells are the predominant targets for 
virus replication. Infection of epithelial cells likely contributes to transmission between 
individuals. Infection of endothelial cells and hematopoietic cells facilitates systemic 
spread within the individual (17).  
1.3 Similarities between HIV and CMV infection 
Although HIV and CMV are fundamentally different viruses, they share some clinical 
features. Both viruses can be transmitted from mother to child, by sexual transmission, 
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and by blood or blood products. Both HIV and CMV infect T lymphocytes. Primary 
infection with both viruses can be asymptomatic or cause a clinical picture similar to 
mononucleosis, with prolonged fever, hepatitis, sore throat, enlarged lymph nodes and 
lymphopenia. Both viruses establish life-long infection in the host, although infection 
with HIV generally has far more severe long-term consequences. 
1.4 Epidemiology 
As a background to understanding HIV and CMV coinfection, the epidemiology of HIV 
and CMV infection will be briefly discussed. 
1.4.1 Epidemiology of HIV infection 
UNAIDS estimated that there were 33.3 million people living with HIV at the end of 
2009, higher than at any time previously in the history of the HIV pandemic (18). In the 
same year it was estimated that there were 2.6 million new cases of HIV infection in the 
world, a considerable drop from 3.1 million in the peak year 1999. Countries with a 
decrease in incidence of >25 % were mainly located in Africa, India and South East Asia. 
In Western, Central, and Eastern Europe, Central Asia, and North America, the rates of 
annual new HIV infections were stable over the previous five years. However, in certain 
risk populations, such as men who have sex with men (MSM), the rate of HIV infection 
has increased in many high income countries, including Norway. In Eastern Europe and 
Central Asia, there are still high rates of HIV transmission among people who inject 
drugs and their sexual partners. 
1.4.2 Epidemiology of CMV infection 
CMV can be transmitted via saliva, urine, placental transfer, blood transfusion, breast 
milk, sexual contact, solid organ transplantation, or bone marrow transplantation. CMV 
seroprevalence varies with sex, age, socio-economic status and geographic location (19). 
Seroprevalence is lowest in Western Europe and in the United States, generally below 
80%. Studies from both Europe and the US have identified non-white ethnicity and low 
socioeconomic status as risk factors for CMV infection. CMV seroprevalence is highest 
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in South America, Africa and Asia, where generally more than 90% of the populations 
are infected. Studies from non-HIV-infected individuals in Africa have found CMV 
seroprevalences between 78% and 100% (20-27).  
Differences in age-related prevalence are probably due to varying child rearing practices, 
sexual behaviours, and living conditions. Breastfeeding, group care of children, crowded 
living conditions, and sexual activity have all been associated with high rates of CMV 
infection (28). A Norwegian study of CMV infection in married couples found that 64% 
were seropositive, and demonstrated an annual seroconversion rate of 1.7% (29). 
Significantly more women than men were seropositive, indicating that men are more 
likely to infect women than vice versa. Another study of Norwegian pregnant mothers 
found that 70% of mothers were seropositive, and estimated a mean annual 
seroconversion rate of 2.4% (30). Seroprevalence generally increases with age, and most 
studies have found that more than 60% are infected by age 50. A Norwegian study of 
kidney transplant recipients and donors found that prevalence was 50% at the age of 20 
years, 80% at 30, and 90 -100% after 60 (31). 
1.4.3 Epidemiology of HIV and CMV coinfection 
In patients with HIV, the seroprevalence of CMV infection varies with the mode of 
acquisition of HIV, and with geographic location. In developed countries, studies of 
HIV-infected MSM have found CMV infection in all or nearly all individuals (32-34). 
This is likely due to the high risk of sexual transmission of CMV in this group. For other 
modes of acquisition of HIV, CMV seroprevalence more closely reflects the situation in 
the general population. In haemophiliacs infected with HIV by factor concentrates in the 
U.S., the prevalence of CMV antibody was 57% (33), and in injecting drug users (IDUs), 
CMV seroprevalence was 67% (34).  
As CMV infection is highly prevalent in developing countries, and HIV and CMV share 
several modes of transmission, it is not surprising that CMV seroprevalence is extremely 
high in HIV-infected populations in this setting. A study from Ghana found that >90% of 
presumably mainly heterosexually acquired HIV positive patients, were also CMV IgG 
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positive (25). Compared to HIV negative individuals, CMV seroprevalence was 
significantly higher for symptomatic HIV-infected individuals, but not for asymptomatic 
individuals. In a study of HIV infection from rural Lesotho, all individuals were CMV 
seropositive (35). 
1.5 Clinical manifestations and immune response in CMV 
infection and disease 
1.5.1 Definitions: CMV infection and disease 
In this thesis I will define CMV infection and CMV disease as follows: 
CMV infection is the state of asymptomatic carriage of the virus in an individual, both in 
the context of latent infection and active replication. CMV infection is usually diagnosed 
by detection of CMV specific antibody.  
CMV disease is the clinical manifestation of CMV caused by active replication or 
immune activation resulting in inflammation or tissue damage. CMV disease can be 
diagnosed by typical ophthalmological findings in the case or CMV retinitis, or by 
typical histopathological findings in tissue specimens (see also section 1.6). CMV 
disease is most common in immunocompromised individuals, but may occasionally 
occur in patients with seemingly well-preserved immunity, usually as a result of primary 
infection. 
1.5.2 The immune response to CMV infection 
CD4+ and CD8+ T cells, natural killer (NK) cells and antibodies that recognise surface 
antigens play a crucial role in the immune response to CMV, preventing the development 
of CMV disease in the immunocompetent host (36). Cellular immunity is particularly 
important, and in non-HIV-infected individuals a high proportion of circulating CD4+ T 
cells and CD8+ T cells are dedicated to the control of CMV in seropositive individuals 
(37). In CMV and HIV-coinfected patients on highly active antiretroviral therapy 
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(HAART), CMV-specific CD8+T cells have been reported to constitute up to 20% of 
circulating T cells (37), twice that of healthy HIV-negative individuals (38;39).  
After allogenic bone marrow transplant patients received transfusion of CMV specific 
CD8+ cytotoxic T cells, the activity of these cells declined in patients deficient in CD4+ 
T cells specific for CMV, suggesting that helper T cell function is needed for the 
persistence of CD8+ T cells (40). In HIV-infected individuals it has been demonstrated 
that after the initial loss of CMV specific CD4+ T cells, there is a subsequent loss in 
function of CMV specific CD8+ T cells. The remaining CD8+ T cells are either unable to 
kill CMV effectively, or unable to proliferate effectively in the absence of CD4+ T cells 
(36;41). 
Results of a recent vaccine trial in patients with solid organ transplantation indicate that 
antibodies play a more important role in conferring protection against CMV disease than 
previously thought (42). In this study, Griffiths et al. used a vaccine containing a 
recombinant form of the envelope glycoprotein B. They found that this vaccine reduced 
both the duration of viraemia, peak viral load, and the total days of ganciclovir treatment. 
There was an inverse relationship between the duration of viraemia and antibody titres, 
further indicating that the protection was mediated by the antibody response to the 
vaccine.  
CMV has developed several ways for evading the host’s immune surveillance and 
defence systems, including both innate and adaptive functions (43). Inhibition of Major 
histocompatibility complex (MHC) class I-restricted antigen presentation is a major 
mechanism, but antigen presentation by the MHC class II pathway is also hindered. In 
addition, CMV produces an interleukin (IL)-10 homologue that binds to the IL-10 
receptor and down-regulates Th1 immune responses (44;45). CMV also produces 
chemokine receptors that bind chemokines and inhibit the immune response and NK cell 
function (46;47).  
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1.5.3 Congenital CMV infection and disease. 
Infection of the fetus can result from active replicating of CMV in the mother during 
pregnancy, both during primary infection, reactivation, and reinfection. Congenital 
infection can cause congenital CMV disease - sensorineural hearing loss and neurological 
impairments being the most common manifestations (48). The fetus is most likely to 
suffer permanent damage if infected as the result of primary maternal infection. CMV 
disease is the most common congenital viral disease and occurs in between 0.2 and 2.2% 
of live births (49).  
1.5.4 CMV disease in immunocompetent children and adults 
In both children and adults, primary CMV infection is normally asymptomatic, after 
which the virus establishes lifelong latency with periodic reactivation (43). In some 
adolescents and adults, primary infection may present as a mononucleosis-like disease 
with prolonged fever, lymphadenopathy, mild hepatitis and lymphocytosis. Occasionally, 
pneumonitis, Guillain-Barré polyradiculitis, transverse myelitis, encephalitis, 
myocarditis, haemolytic anaemia, thrombocytopenia and other complications have been 
observed in immunocompetent individuals (16). 
1.5.5 CMV disease in immunocompromised individuals 
In immunocompromised individuals, CMV primary infection, reactivation and 
reinfection may cause severe disease with a high case fatality unless diagnosed and 
treated appropriately at an early stage. This is a well known complication after both bone 
marrow transplantation and solid organ transplantation (50;51). In addition to end-organ 
disease, CMV infection may have indirect effects, and is associated with allograft 
pathology, including atherosclerosis, bronchiolitis obliterans, vanishing bile duct 
syndrome, vascular disease, and both acute and chronic graft rejection (52). 
Before HAART was available, CMV disease was the most common serious opportunistic 
viral disease in patients with HIV infection (53-58). CMV disease is rare in patients with 
CD4+ T cell counts >100 cells/mm3. The risk of CMV disease increases as CD4+ T cell 
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counts drop <100 cells/mm3, and increases dramatically <50 cells/mm3 (57;59;60). Prior 
to the HAART era, the most common manifestation of CMV disease in patient with 
AIDS was retinitis, usually progressing to blindness within months unless appropriate 
therapy was given (61). Other commonly affected organs were the gastrointestinal tract, 
the nervous system, and the adrenal glands. CMV seropositive individuals with sexual 
exposure as the risk factor for acquisition of HIV were reported to have higher risk of 
CMV disease than persons infected by other modes of transmission, such as injecting 
drug use and transfusion of blood products (34). 
During the pre-HAART era, increasing incidence rates for CMV disease were observed 
in patients with HIV. This was probably due to longer survival of patients with severe 
immunodeficiency, caused by improved PCP prophylaxis and advances in the treatment 
of opportunistic infections (62;63). Later, after the introduction of HAART, a dramatic 
fall in the incidence of CMV disease was observed (64-71). However, CMV disease 
continues to occur both in antiretroviral naïve and experienced individuals (69;72-74). A 
typical example of the situation in a developed country before and after the introduction 
of HAART in 1996 is shown in Figure 1.  
In resource-poor settings, there are relatively few studies that have examined the 
occurrence of CMV disease in HIV-infected individuals (75). As CMV disease primarily 
occurs in patients with advanced immunodeficiency, it has been suggested that patients in 
developing countries generally die from opportunistic infections such as tuberculosis and 
pneumocystosis that present at less advanced stages of HIV infection, (24;76;77). 
However, CMV disease may represent a significant cause of morbidity in CMV 
seropositive patients with advanced HIV infection even in resource- poor countries 
(78;79). 
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Figure 1. Number of cases of CMV disease in HIV-infected individuals at the Department 
of Infectious Diseases, Oslo University Hospital, during the period 1985 – 2011. 
 
1.6 Diagnosis of CMV disease in immunocompromised 
individuals 
Patients with CMV retinitis often experience blurring or loss of central vision, scotomata, 
floaters or photopsia (“flashing lights”). This manifestation can be reliably diagnosed by 
ophthalmoscopy by an experienced ophthalmologist. Typical features include white 
fluffy retinal infiltrates, and areas of haemorrhage (Fig. 2). CMV retinitis can also appear 
as a granular white area without haemorrhage (16).  
The clinical features of CMV disease in other end-organs are generally non-specific, and 
symptoms such as fever, malaise, anorexia, diarrhoea, muscle and joint pain are common. 
In case of extraocular manifestations of CMV disease, histopathological findings typical 
of CMV disease are required for confirmation of the diagnosis. Typical findings include 
enlarged cells and nuclei with intranuclear inclusion bodies, often giving an “owl’s eye 
appearance” (Fig. 2). 
0 
5 
10 
15 
20 
25 
19
85
 
19
86
 
19
87
 
19
88
 
19
89
 
19
90
 
19
91
 
19
92
 
19
93
 
19
94
 
19
95
 
19
96
 
19
97
 
19
98
 
19
99
 
20
00
 
20
01
 
20
02
 
20
03
 
20
04
 
20
05
 
20
09
 
20
10
 
20
11
 
extraocular CMV disease 
CMV retinitis 
Introduction 
 
21 
 
 
 
Figure 2. Diagnosis of CMV end-organ disease. The left photograph shows a typical 
example of CMV retinitis with white fluffy retinal infiltrates and areas of haemorrhage. 
The right photograph shows a typical example of CMV encephalitis with cytomegalic 
cells and inclusions. 
 
Several studies have demonstrated that CMV disease is under-diagnosed in HIV-infected 
patients, and that the diagnosis is often first made at autopsy (53-56;58;80-88). With the 
aim of identifying patients at high risk, reducing the time to diagnosis and possibly 
eliminating the need for biopsies, a variety of microbiological tests for detection of CMV 
have been assessed.  
Demonstration of CMV specific antibody is of limited utility for diagnosis of CMV 
disease, but the absence of anti-CMV IgG antibody makes the diagnosis unlikely (89).  
CMV can be cultured from blood and other tissues, but is generally not very helpful in 
the diagnosis of CMV disease (90). Currently, culture is mostly performed for the 
purpose of susceptibility testing when antibiotic resistance is suspected. Isolation of 
CMV in culture demonstrates that the virus is present, but sensitivity and specificity for 
CMV disease is poor. Shedding of virus is common in the absence of disease, and the 
sensitivity is lower than newer nucleic acid amplification tests. 
Introduction 
 
22 
 
CMV antigenaemia assays using monoclonal antibodies to detect pp65 proteins in 
peripheral blood leukocytes have been widely used in patients at risk of CMV 
reactivation and disease, both in transplant and HIV-infected patients (91-98). Although 
these tests perform well, different nucleic acid tests (NATs), including polymerase chain 
reaction (PCR), hybrid capture, and nucleic acid sequence based amplification (NASBA), 
are now in more common use. They are fast and reliable, can provide a quantitative 
result, and have been used to detect CMV DNA in blood (including whole blood, 
peripheral blood leukocytes and plasma) (65;92;98-110), and cerebrospinal fluid (111-
114). Several studies have found that detection of CMV DNA in blood by PCR is a risk 
factor for subsequent development of CMV disease (65;92;96;98;99;101-
104;107;109;110;112;115-118). However, the reported sensitivities specificities, positive 
and negative predictive values have varied greatly (100;101;103;105;107;119). 
1.7 Prophylaxis and treatment of CMV disease 
In immunocompetent individuals there is generally no indication for treatment of CMV 
infection and disease. However, CMV infection may lead to life-threatening disease in 
immunocompromised individuals, in whom therapy is clearly warranted. Potential 
management modalities include prophylaxis to high risk individuals, pre-emptive therapy 
to patients with asymptomatic CMV viraemia, and treatment of manifest CMV end-organ 
disease. In solid organ and bone marrow transplant patients, all these modalities are used 
(51;120).  
Drugs against CMV include the nucleosides ganciclovir and aciclovir, the nucleotide 
cidofovir, foscarnet and fomivirsen. With the exception of fomivirsen, these all act by 
inhibiting CMV DNA polymerase. Fomivirsen is an antisense compound for intravitreal 
use that acts by blocking the major immediate-early transactivator gene of CMV.  
For treatment of CMV diseases in patients with HIV, intravenous foscarnet and 
ganciclovir have been shown to reduce the progression of retinitis and other end-organ 
manifestations (121-125). Intravenous cidofovir is also effective for treatment of retinitis, 
but is associated with serious nephrologic side effects (126;127). Oral valaciclovir, a 
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prodrug of aciclovir, has activity against CMV (118;128), but is no longer recommended 
for treatment, as oral valganciclovir is more effective. Valganciclovir is a prodrug of 
ganciclovir that has shown equal efficacy as intravenous ganciclovir for treatment of 
CMV retinitis (129). The ganciclovir intraocular device is also effective in the treatment 
of CMV retinitis (130;131), but this should preferably be combined with oral 
valganciclovir to prevent development of retinitis in the contralateral eye.  
A recent trial concluded that pre-emptive therapy with oral valganciclovir was not 
warranted in HIV-infected individuals given the low incidence of CMV disease in 
patients with access to HAART (132). 
Resistance to ganciclovir commonly results from mutations in the gene UL97 coding for 
protein kinase, and less commonly by mutations in the UL54 gene coding for DNA 
polymerase, which can lead to resistance to ganciclovir, cidofovir, and sometimes 
foscarnet (133). 
1.8 CMV as a cofactor for progression of HIV infection 
There are several potential ways in which CMV could act as a cofactor for HIV infection, 
defined as “an infectious agent which interacts at the molecular or cellular level to 
promote HIV pathogenicity” (134). By mechanisms outlined below, CMV replication 
may drive HIV replication to higher levels, which again may cause more rapid CMV 
replication, thus creating a vicious circle, as demonstrated in Figure 3.  
 
Figure 3. Pathways leading to opportunistic vs. cofactor relationships between CMV and 
HIV. (From: Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J.Clin.Virol. 
2006; 35: 489-92).  
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The result may be CMV disease, but also faster progression of HIV disease to new AIDS 
defining conditions or death. Studies solely focusing on CMV end-organ disease may 
underestimate the potential cofactor effect of asymptomatic CMV viraemia.  
1.8.1 Potential immunological mechanisms for the cofactor effect of CMV 
In vitro, several potential mechanisms for enhancing effects of CMV infection on HIV 
disease have been demonstrated (135-137): 
x CMV activation of latent proviral HIV DNA by introduction of its transactivator 
proteins into the same cell (138;139).  
x CMV activation of HIV latent provirus by release of cytokines from nearby cells 
by signal transduction (140). 
x CMV antigen release from a nearby cell leading to activation of latent HIV 
provirus when HIV is latent in a T memory cell whose cognate antigen receptor is 
specific for a CMV-encoded protein (141). 
x CMV-induced change in the tropism of HIV-infected cells. If CMV and HIV 
infect the same cell, the tropism of HIV could by altered by forming pseudotypes 
that would also be able to bind to other cells containing receptors for CMV (142). 
The US28 gene of CMV codes for a chemokine receptor that can permit entry of 
HIV into CD4+ T cells not depending on CCR5 (143). Alternatively, CMV could 
activate CD4 expression within cells that are CD4 negative (144). CMV could 
code for a molecule acting as an alternative receptor for HIV; for example HIV 
coated in non-neutralising antibodies can enter fibroblasts via an Fc receptor 
coded for by CMV (145). 
1.8.2 Evidence of cofactor effect from epidemiological studies 
There are some indications that CMV infection is linked to poor prognosis for patients 
with HIV infection, but results are conflicting. Some observational studies of HIV-
infected adults in developed countries have reported that CMV seropositivity is 
Introduction 
 
25 
 
associated with more rapid rate of progression of HIV disease to a more advanced stage 
(3;135;146-148). Also, in children it has been demonstrated that HIV-1-infected infants 
who acquire CMV infection in the first 18 months of life have a significantly higher rate 
of disease progression and central nervous system disease than those infected with HIV-1 
alone (149). In contrast, Rabkin et al. did not find that seropositivity was significantly 
linked to development of AIDS or risk of death in haemophiliacs (150). Shepp et al. also 
failed to find an association between CMV serological status and survival in a more 
heterogeneous HIV-infected population (34).  
Many studies from developed countries have found that CMV viraemia is associated with 
poor prognosis (73;104;109;110;115;116;151;152). Detels et al. reported that patients 
with persistent excretion of CMV in semen had a significantly increased relative hazard 
of developing AIDS (153). However, few studies from developing countries have 
addressed the impact of CMV infection and viraemia on survival of HIV-infected 
individuals. In a study from Cambodia, serum CMV replication was highly prevalent 
among HIV-infected patients and was associated with increased mortality (154). 
1.9 CMV-related immune activation, inflammation and 
immunosenescense 
HAART has resulted in greatly improved life expectancy for individuals with HIV 
infection. Nevertheless, as a group these individuals are at greater risk of age-related 
disorders, such as certain malignancies, cardiovascular disease, type II diabetes, and 
cognitive impairment than persons without HIV infection. This may be related to the 
observation that HIV-infected individuals often have an immune risk phenotype that is 
more typical of older non-HIV-infected persons, and associated with poor prognosis 
(155). Many HIV-infected individuals continue to have abnormal T cell activation 
despite antiretroviral treatment (156-159), and this is associated with attenuated CD4+ T 
cell recovery (157).  
Recent studies indicate that CMV infection increases all-cause mortality in the elderly 
non-HIV-infected population and raises the risk of many age-related diseases (155). This 
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increased risk may at least in part be due to CMV mediated inflammation resulting in a 
disadvantageous immune risk phenotype (155). Chronic inflammation is also a probable 
explanation for the increased risk of age-related disorders observed in HIV-infected 
individuals (160). This may be aggravated by the deleterious immunological effects of 
CMV in coinfected individuals.  
Fibrinogen and CRP are markers of inflammation that have been shown to be 
independent predictors of mortality in HIV-infected adults (161). The same has been 
reported for the inflammatory cytokine IL-6 (162). Inflammation is associated with 
depletion of CD4+ T cells and is also a likely cause of increased risk of cardiovascular 
disease in patients with HIV. Increased carotid intima thickness in HIV patients is 
associated with increased CMV specific T-cell response (163). Also, CMV IgG antibody 
titres have been shown to be positively associated with degree of coronary 
atherosclerosis, suggesting that immune activation and CMV-specific immune response 
may contribute to atherosclerosis in HIV-infected patients (164;165). In a recent clinical 
study by Hunt et al., valganciclovir reduced T cell activation in HIV-infected individuals 
with incomplete CD4+ T cell recovery on antiretroviral therapy (166). It was concluded 
that CMV and/or other herpesvirus replication is a significant cause of immune activation 
in this population. 
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2 Aims and objectives 
2.1 Main aim 
The overall aim of this thesis was to gain new knowledge of CMV infection in HIV-
coinfected individuals, including aspects of epidemiology, diagnosis, clinical 
manifestations, and prognosis. 
2.2 Specific objectives  
I. To study the incidence of CMV disease in patients with AIDS in Norway in the 
pre-HAART era (Paper I) 
II. To examine the impact of CMV infection and CMV end-organ disease on 
survival in patients with AIDS in Norway in the pre-HAART era (Paper I)  
III. To explore the utility of plasma CMV quantitative PCR in the diagnosis of CMV 
disease in patients with HIV-infection (Paper II)  
IV. To assess the utility of dried blood spots (DBS) for detection of CMV antibody 
and CMV viraemia in HIV-infected individuals in a resource-poor setting (Paper 
III) 
V. To study the prevalence of CMV infection and viraemia in relation to clinical 
outcome in patients with HIV infection and access to HAART in rural Tanzania 
(Paper III) 
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3 Materials and methods 
Details of the study populations, study periods, study designs, diagnostic methods and 
outcome variables are provided in each paper, but an overview is shown in Table 1 and in 
the description below. 
3.1 Study populations, periods, designs, and outcomes  
In Papers I and II, potentially eligible patients were identified in the HIV database at the 
Department of Infectious Diseases, Oslo University Hospital. The studies presented in 
these papers comprised patients with advanced HIV infection in this hospital. In Paper I, 
248 patients with a clinical diagnosis of AIDS during the years 1983-1995 were included. 
In Paper II, we included 125 patients with HIV-related death during the years 1991-2002 
(53 with CMV disease and 72 without CMV disease) in whom autopsy was performed. 
Only 45 of 125 patients (36%) were tested for HIV viral load and 15 (12%) had HIV 
RNA <400 copies/ml, all in patients without CMV disease. Ten of 53 patients with CMV 
disease were tested for HIV viral load, all of whom had high-level viraemia. 
In the study presented in Paper III, 168 HIV-infected and antiretroviral naïve patients 
presenting to Haydom Lutheran Hospital during 2008-2010 were included. 
MSM comprised the majority of the Norwegian study populations (Paper I and II), 
whereas heterosexually infected women comprised the majority of the study population 
in Tanzania (Paper III). 
In all studies, inclusion criteria and outcomes were verified by detailed review of patient 
files.  
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Table 1. Overview of study populations, periods, designs, diagnostic methods and main 
outcomes in Papers I, II, and III. 
Paper 
no.  
Study 
population 
Study 
period 
Study design Diagnostic methods Main 
outcomes 
I 248 patients with 
AIDS in Oslo  
1983-
1995 
Retrospective 
cohort 
Ophthalmoscopy, 
biopsy,  
autopsy 
CMV 
disease 
Death 
 
II 125 CMV and 
HIV seropositive 
deaths in Oslo 
with autopsy 
results 
 
1991-
2002 
Diagnostic 
study 
CMV quantitative 
PCR in plasma, 
autopsy 
CMV 
disease 
 
III 168 antiretroviral 
naive patients in 
rural Tanzania 
2008-
2010 
Prospective 
cohort study 
CMV antibody and 
quantitative PCR in 
dried blood spots 
Death 
 
3.2 Diagnostic methods 
3.2.1 Detection of CMV IgG antibody 
In all papers, CMV antibody was determined using commercially available and validated 
antibody tests in routine use at the time at the Department of Microbiology, Oslo 
University Hospital. For the years 1985-1996 the test used was Enzygnost (Enzyme-
linked Immunosorbent Assay, ELISA), from 2010 Abbott Axzym (ELISA), and from 
2010 Abbott Architect (chemiluminescent microparticle immunoassay, CMIA).  
3.2.2 Analysis of CMV viraemia by quantitative PCR 
In Papers II and III CMV quantitative PCR was performed in plasma and dried blood 
spot eluates, respectively. In paper III we performed an additional exploratory assessment 
of the performance of our CMV quantitative PCR methodology in DBS eluates, by 
comparing with results from 11 plasma samples prepared in parallel. All CMV PCR 
positive plasma samples were positive in DBS eluates, and negative samples were 
negative by both methods. There was good correlation between measured CMV viral 
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load in DBS and plasma (r = 0.87, p <0.001) although detected viral load tended to be 
lower in DBS.  
3.2.3 Diagnosis of CMV disease 
In all papers we used a strict case-definition (see section 1.5.1). A diagnosis of CMV 
retinitis ante-mortem was based on typical ophthalmoscopic findings (see section 1.6). 
Routine ophthalmoscopy was not performed in individuals at high risk of CMV disease, 
but was performed in patients presenting with suggestive symptoms. The characteristic 
histopathological features of cytomegalocytes with inclusions were required for diagnosis 
of all other end-organ manifestations of CMV disease. Demonstration of CMV by culture 
or PCR of biopsies, blood or urine without histopathological verification was not 
accepted for diagnosis. In the autopsy group, a full necropsy including neuropathological 
examination was performed, except for the adrenal glands, the gastrointestinal tract, and 
the eyes in some cases. Paraffin-embedded sections were routinely stained with 
haematoxylin–eosin, but additional immunohistochemistry for CMV was performed in a 
few cases of doubt to confirm the presence of CMV. Histopathological examination was 
not available for diagnosis of CMV disease in study III. 
3.3 Statistical analysis 
For group comparison of continuous variables conforming to the normal distribution, 
two-sample t-tests were used. Non-parametric tests were used for group comparison of 
variables not conforming to the normal distribution, using Mann-Whitney U-tests for 
independent samples and Wilcoxon signed rank tests for related samples. χ2 tests and 
logistic regression were used for comparison on categorical data. Correlation between 
variables was assessed by Spearman rank coefficients.  
Paper I and III were cohort studies in which survival probabilities were presented as 
Kaplan-Meier plots. Cox regression analyses were used to calculate hazard ratios for 
mortality during the follow-up periods, entering baseline variables and time-dependent 
variables in the models, as appropriate. In paper III, we used a forward selection 
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technique, as outcomes were too few to allow us to enter all independent variables into 
the model simultaneously.  
Paper II was a diagnostic study in which sensitivity and specificity, positive and negative 
predictive values for different cut-offs of CMV viral load were calculated. Results were 
also presented as a receiver operating characteristic (ROC) curve with the area under the 
curve representing the diagnostic accuracy of the test.  
3.4 Ethical considerations 
Approvals from the concerned authorities were obtained, as required. This included 
approval from the Regional Committee for Medical and Health Research Ethics in 
Norway, and the Medical Research Coordinating Committee in Tanzania. In paper II we 
used stored samples from the approved Biobank at Oslo University Hospital, Department 
of Infectious Diseases. In paper III, patients gave written consent to participate in the 
study.  
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4 Summary of results 
4.1 Paper I: CMV disease in patients with AIDS in Oslo  
x  92.9% of the tested sera were CMV seropositive. Seroprevalence in MSM was 
99.4%, in IDUs 71.1%, and was 83.3% in other risk groups combined. There was 
significantly higher CMV seroprevalence in MSM than in IDUs (p <0.0001). 
x 95 of 248 patients (38.3%) developed CMV disease during the study period. 
Among autopsy cases, 73 of 152 patients (48%) had histopathological evidence of 
CMV disease, and 52 (71%) of these were first diagnosed at autopsy. 
x Among patients who died (n =213), the most common manifestations of CMV 
disease were retinitis (23%), adrenalitis (20%), pneumonitis (16%), and 
gastrointestinal disease (9%).  
x All patients diagnosed alive with CMV had evidence of CMV disease at autopsy, 
despite CMV therapy. 
x The proportion of cases with CMV disease increased from 39% during the period 
1983-89, to 51% during the period 1990-95. 
x There was no significant difference in survival between CMV seropositive and 
seronegative individuals. 
x CMV disease diagnosed alive was associated with increased risk of death. 
4.2 Paper II: CMV quantitative PCR for diagnosis of CMV end-
organ disease in HIV infection 
x CMV viraemia was detected in at least one sample in 27 of 53 patients with CMV 
disease (51%) and in 10 of 72 patients (13%) without CMV disease (p <0.001). 
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x CMV viral load was significantly higher in patients with CMV disease than in 
patients without disease (p = 0.001). Among viraemic patients there was no 
significant difference in CMV viral load between the two groups, median 3420 
copies/ml and 1705 copies/ml, respectively. 
x The proportions of cases with viraemia were similar for patients diagnosed with 
CMV disease alive and at autopsy, 44% and 49%, respectively. 
x In patients with multi-organ CMV disease and single-organ CMV disease the 
proportions with detectable CMV in plasma were 70% and 24% respectively, p = 
0.005. 
x Diagnostic sensitivity, specificity, positive predictive value and negative 
predicative values for patients with detectable CMV were 47%, 89%, 76%, and 
70%, respectively.  
x In patients with CMV PCR >10 000 copies/ml in a single sample, or any level of 
viraemia in two consecutive samples, diagnostic specificity and positive 
predictive values were 100%. 
x CD4+ T cell count <100 cells/mm3 and high viral load were significantly 
associated with risk of CMV disease in multivariable analysis.  
4.3 Paper III: CMV viraemia in DBS in relation to survival in HIV-
infected patients in Tanzania  
x All patients were CMV seropositive. 
x 38 of 168 Tanzanian patients (22.6%) had detectable viraemia at baseline and 14 
(8.3%) had CMV viraemia >200 copies/ml.  
x CMV viraemia >200 copies/ml represented a significant risk factor for death in 
multivariable analysis. 
x Among 51 patients with CD4+ T cell counts <100 cells/mm3, 11 (21.6%) had 
CMV viraemia >200 copies and were at high risk of CMV disease. 
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5 Discussion 
The study presented in Paper I was initiated in the mid-1990ies, before the HAART era. 
At the time, the infectious disease wards at Oslo University Hospital provided care for a 
large number of HIV-infected patients with serious opportunistic diseases and other 
complications such as PCP, disseminated Mycobacterium avium intracellulare infections, 
candida oesophagitis, and Kaposi’s sarcoma. CMV disease was also a common 
occurrence. During this period, Oslo University Hospital had a higher autopsy rate for 
HIV-related deaths than most similar clinics in other countries. This represented a clear 
advantage in the study of CMV disease – a complication of HIV infection that too often 
was diagnosed at the autopsy table. We found that almost one-half of the patients had 
evidence of CMV disease at autopsy, and that this diagnosis in most cases was not 
known before death. Furthermore, a diagnosis of CMV disease alive was identified as a 
significant risk factor for death. 
Paper I clearly demonstrated that improved methods were needed for timely diagnosis of 
CMV disease. In the study presented in Paper II, we therefore assessed CMV quantitative 
PCR as a tool for early diagnosis of CMV disease. In this study, which covered a period 
both before and after introduction of HAART, we found that the diagnostic sensitivity of 
CMV viraemia was relatively poor, but that clinical specificity was good for patients 
with high CMV viral load or repeated viraemia. 
After the introduction of HAART in 1996-97, a rapid drop in the incidence of CMV 
disease was observed in Norway and other developed countries. However, little is still 
known about the impact of CMV viraemia and disease on prognosis of HIV-infected 
individuals in developing countries. This is largely due to challenges with ensuring a 
correct diagnosis, be it with by fundoscopy by an experienced ophthalmologist, biopsy, 
or autopsy – procedures that are rarely available in these settings. Also, CMV viraemia 
assays are seldom available in resource-poor countries. This is partially due to 
unavailability of these advanced microbiological tests, but also related to logistical 
challenges with ensuring correct transport and storage of liquid specimens. DBS 
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specimens have potential logistical advantages, as they are more robust to ambient 
temperatures, and less prone to transport damage. DBS have previously proved useful for 
quantification of HIV viral load, and for HIV resistance testing (167;168). In Paper III, 
we report results of CMV antibody and viraemia assays performed in DBS eluates from 
HIV-infected individuals in Tanzania, and relate our findings to survival. We found that 
all patients were CMV IgG antibody positive and that CMV viral load >200 copies/ml in 
DBS eluates was a risk factor for death. 
5.1 Methodological considerations 
A detailed discussion of our methods can be found in each paper, but certain additional 
and general aspects are treated in more detail below. 
5.1.1 CMV antibody  
In Paper I, 4% of individuals were not tested for CMV antibody, and 7% were CMV IgG 
negative. As CMV antibody was not systematically retested in CMV negative individuals 
during the study period, it is possible that a few cases of seroconversion may have been 
missed. In this paper, we might therefore have slightly underestimated CMV 
seroprevalence. In Paper II, known CMV seropositivity was one of the inclusion criteria. 
In Paper III, all patients were CMV IgG positive in DBS eluates at baseline. Although 
this test has not been validated for use in DBS, all patients had high arbitrary unit (AU) 
values, and we find it unlikely that there should be a problem with false positive tests. 
5.1.2 CMV quantitative PCR and assessment of test performance 
Detection of CMV viraemia by PCR can be performed by both qualitative and 
quantitative tests. Today, quantitative tests are most commonly used, as knowledge of the 
amount of virus, not only presence or absence, may have clinical implications. In patients 
with HIV-infection and CMV viraemia, the risk of CMV disease or death has been 
shown to increase with rising viral load (104;115;116;152). Also, viral load can be used 
to monitor the effect of therapy and emergence of resistance (152). 
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In Paper II, we used a commercial CMV quantitative PCR test (Cobas Amplicor CMV 
Monitor Test). We assessed this test’s clinical sensitivity and specificity, and calculated 
positive and negative predictive values for CMV disease. 
It is important to distinguish between analytical and diagnostic sensitivity, and analytical 
and diagnostic specificity of a test. The analytical sensitivity represents the smallest 
amount of substance in a sample that can accurately be measured by an assay (169). 
Synonyms for “analytical sensitivity” are “limit of detection” and “minimal detectable 
concentration”. Diagnostic sensitivity is the percentage of persons with a disorder who 
are identified by the assay as positive for the disorder. High analytical sensitivity does 
not guarantee acceptable diagnostic sensitivity.  
In general, poor diagnostic sensitivity may have several explanations. First, it may be due 
to poor analytical sensitivity. In Paper II we used the Cobas Amplicor CMV Monitor 
Test. This is a well validated assay with relatively high analytic sensitivity. Second, 
diagnostic sensitivity can be reduced by failure to obtain the target substance in a 
processed sample from a person with the condition of interest. We tested frozen plasma 
samples taken at various intervals before CMV disease was confirmed or excluded. It is 
therefore possible that some patients did not have detectable CMV viraemia in a sample 
because it was taken too early or too late in relation to the final diagnosis, or that we 
failed to detect intermittent viraemia. Finally, diagnostic sensitivity may change with 
variation in the clinical spectrum of a disease. We found that diagnostic sensitivity was 
highest in patients with more severe disease, as determined by CMV disease in more that 
one organ (see section 5.3.1). 
Analytical specificity refers to the ability of an assay to detect one particular organism or 
substance, rather than others. The diagnostic specificity represents the percentage of 
persons who do not have a given condition who are identified by the assay as negative 
for the condition. Poor diagnostic specificity may be due to poor analytic specificity, and 
failure to diagnose the disease in question when it is in fact present. Diagnosis of CMV 
end-organ disease may be challenging, as it often requires invasive procedures and 
examination of histopathological specimens. In addition, CMV viraemia may precede 
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manifest CMV disease by several months, and a sufficiently long observation period is 
therefore required in cohort studies. Failure to diagnose a condition due to short 
observation time or insufficient use of invasive procedures can potentially contribute to 
poor specificity. In Paper II we followed all patients to death, and autopsy results were 
available for all. We were therefore unlikely to miss cases with CMV disease and to 
underestimate the specificity of the test.  
The positive predictive value is the probability that a person whose test result is positive 
truly has the disease or condition of interest. The negative predictive value is the 
probability that a person whose test result is negative does not have the disease. In 
addition to the diagnostic sensitivity and specificity, the predictive values are highly 
dependent on the prevalence of the condition of interest in the population being tested. 
High diagnostic sensitivity and low prevalence of the condition in question give a high 
negative predictive value. High diagnostic specificity and high prevalence of the disease 
result in high positive predictive value. In Paper II, we calculated positive and negative 
predictive values of CMV quantitative PCR for diagnosis of CMV disease. In this study, 
CMV disease was common, and this contributed strongly to the generally high positive 
predictive values and low negative predictive values. (See also section 5.3.1).  
In Paper III, we used DBS as samples for detection of CMV viraemia. One aim was to 
study if CMV viraemia was associated with increased mortality in a rural Tanzanian 
population. It was not our ambition to directly compare results from DBS with results 
that might have been obtained if the analysis had been carried out using liquid plasma 
samples. We therefore chose not to perform an in-depth validation of CMV quantitative 
PCR in DBS eluates compared to plasma, but to limit our assessment to establishing 
satisfactory correlation between the two methods. In an exploratory study, performed 
prior to testing samples from Tanzanian HIV-infected individuals, the test performance 
of the artus CMV TM PCR Kit in DBS eluates was compared to the performance of the 
Cobas Amplicor CMV Monitor Test in plasma. We demonstrated good correlation 
between the tests (r = 0.87, p <0.001), but found that CMV viral load in DBS eluates 
tended to underestimate viral load in plasma samples collected in parallel.  
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The most likely explanation for lower viral load in DBS than in plasma is that a smaller 
proportion of CMV DNA was successfully extracted from DBS than from plasma 
samples. Another possible explanation is degradation of CMV DNA in DBS due to 
storage, including freezing and thawing of specimens. However, CMV DNA is known to 
be robust to degradation (170;171), and this is unlikely to be a major factor. A last 
potential explanation for discrepancies between DBS and plasma results is that two 
different CMV quantitative PCR assays were used. However, the artus CMV TM PCR 
Kit and Cobas Amplicor CMV Monitor Test have generally shown good agreement 
(172).  
In Paper III, our test of CMV viraemia in DBS may have failed to detect some patients 
with low viral load in plasma, and we may have underestimated the viral load of patients 
with detectable viraemia. This may reduce the diagnostic sensitivity of CMV quantitative 
PCR in DBS compared to plasma. However, the clinical significance of this is uncertain. 
In transplant patients, CMV viral load <100-500 copies/ml is of unknown significance 
and may be difficult to interpret (173). Similarly, low CMV viral load in HIV-infected 
patients may have low positive predictive value for CMV disease or death.  
5.1.3 Diagnosis of CMV retinitis and other end-organ disease 
In studies of CMV disease in HIV-infected individuals, clear case definitions are required 
and have been proposed (132). Definitions of CMV infection and disease in transplant 
recipients are not directly applicable to HIV-infected individuals (174), and for patients 
with HIV there is no universally accepted definition of CMV disease. Nevertheless, most 
studies of CMV disease in HIV coinfected individuals have applied stringent case 
definitions for the diagnosis of CMV disease. We required histopathological evidence of 
CMV disease by biopsy or autopsy, except for retinitis diagnosed by typical 
ophthalmological findings. Demonstration of CMV by culture of biopsies, blood or urine 
without histopathological verification was not accepted for diagnosis, as these are 
unspecific findings (16). Routine ophthalmoscopy was not performed in individuals at 
high risk of CMV disease, but was done when patients presented with suggestive 
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symptoms. It is therefore possible that we may have missed some cases of early CMV 
retinitis in all three studies. 
5.2 CMV infection and disease in patients with AIDS 
5.2.1 CMV seroepidemiology 
In Paper I, 99.4% of HIV-infected MSM were CMV IgG positive, compared to 71.1% in 
IDUs (p <0.001). Our findings are in accordance with other studies that have found CMV 
infection to be almost universal in MSM (32-34). CMV infection in IDUs was slightly 
more common than in previous studies of Norwegian married couples and pregnant 
mothers (29;30), perhaps reflecting a higher seroprevalence associated with lower 
socioeconomic status (19). In addition, transmission of CMV by sharing of needles is 
possible.  
In Paper III from Tanzania, all patients were CMV IgG seropositive, i.e. comparable to 
MSM in Norway. Other studies have also found CMV seroprevalence >90% in HIV-
infected individuals in developing countries (25;35). 
5.2.2 Occurrence of CMV disease 
5.2.2.1 Occurrence of CMV disease in Norway 
Paper I represents the only published Scandinavian study of the occurrence of CMV 
disease in HIV-infected individuals. This was a large population based study comprising 
the majority of AIDS patients in Oslo during the period 1983-95, before HAART was 
available. During this period, autopsy was performed in 71% of AIDS deaths. This 
proportion is higher than reported in all other autopsy-based studies of CMV disease 
(55;58;80;81), and reduces bias that may occur in more selected populations. Table 2 
summarises results from previous autopsy-based studies in developed countries in which 
the prevalence of CMV disease has been assessed. 
In Paper I, we found evidence of CMV disease at autopsy in 48% of the cases. In similar 
studies from other countries, the proportion with CMV disease at autopsy has varied 
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from 28% to 81% (53-56;58;80-88). We found that retinitis was the most common 
manifestation of CMV disease, in agreement with other studies (61;69;80;175). Although 
most cases of retinitis were diagnosed before death, only a minority of the other CMV 
end-organ manifestations were diagnosed prior to autopsy. These results demonstrated a 
clear need for more timely diagnosis of CMV disease. 
In Paper II, we included patients with AIDS who died during the period 1991-2002, i.e. 
encompassing years both before and after HAART was introduced. In this study, CMV 
disease was found in 42% of patients at autopsy, i.e. less commonly than in Paper I, 
which only included patients in the pre-HAART era. Furthermore, as CMV IgG 
positivity was one of the inclusion criteria in Paper II, our estimated prevalence of CMV 
disease at autopsy likely represents a slight overestimation of the prevalence in all HIV-
related deaths. This overestimation is likely to affect IDUs most, as a not insignificant 
proportion of individuals in this group was CMV seronegative. Our results are consistent 
with other studies that have demonstrated a reduction in the incidence of CMV disease 
after the introduction of HAART (64-70).  
In Paper II, all cases with CMV disease with a known result of HIV viral load had high-
level HIV viraemia. This is consistent with a cohort study by Erice et al. where all CMV 
end-organ events occurred in patients with high HIV viral load (109). Deayton et al. has 
demonstrated that effective HAART can suppress CMV viraemia (176). Currently, CMV 
disease is uncommon in HIV patients in Norway as in other developing countries. 
Nevertheless, CMV disease continues to be reported in low numbers in patients 
presenting late with advanced HIV infection, and may also occur in patients with poor 
treatment adherence, or resistant virus (69;72-74).  
An epidemiological study from Europe for the period 1994-2001 found that CMV end 
organ disease was the cause of the death in 18% of cases (69), but the number of cases in 
which the cause of death was determined by autopsy was not reported. In the same study, 
the median survival was 10 months for patients with any CMV disease manifestation, 11 
months for retinitis and seven month for other CMV organ disease. By multivariable 
analysis, the commencement of HAART was associated with a 37% decrease in mortality 
Discussion 
 
43 
 
(p <0.05). In a French study of HIV-infected individuals, median survival was seven 
months for CMV disease, and initiation of therapy with protease inhibitor was associated 
with increased survival (177). 
Soon after the introduction of HAART, CMV retinitis was observed in patients with 
previously low CD4+ T cell counts even after counts rose >100 cells/mm3 (178). In 
addition, a new CMV-related manifestation of the eye was reported, known as immune 
recovery uveitis (179). The pathogenesis of both retinitis and uveitis in this setting is 
probably explained by immune reaction to low-level CMV replication or residual CMV 
antigens.  
5.2.2.2 Occurrence of CMV disease in rural Tanzania 
In Paper III, we identified no patients with a confirmed diagnosis of CMV disease, 
neither retinitis nor other end-organ disease. This may at least in part due to diagnostic 
constraints, as ophthalmoscopy was the only diagnostic modality available. Severe cases 
of symptomatic retinitis were unlikely to have been missed. However, mild cases of 
retinitis might have been overlooked, as routine ophthalmoscopy was not performed in 
patients with low CD4+ T cell counts. Due to non-availability of histopathological 
examination of tissue specimens, we were unable to diagnose patients with CMV disease 
in organs other than the eyes. However, we found that patients at high risk of CMV 
disease, by having both low CD4+ T cell counts and high CMV viral load, often had non-
specific symptoms such as fever and diarrhoea that were compatible with CMV disease.  
From other developing countries, we have some knowledge about the impact of CMV 
disease in HIV-infected individuals. In Thailand and India the prevalence of CMV 
retinitis in patients with HIV has been reported to be 33% and 17%, respectively 
(180;181). In Africa, CMV retinitis appears to be less common, with reported prevalence 
in cross-sectional surveys ranging from 0.0%–8.5% (76;182;183). It has previously been 
speculated that low prevalence of CMV disease in Africa may be due to high competing 
mortality from other opportunistic diseases (24;76;77). However, studies published in 
recent years indicate that other factors also may be at play. In two comparative cohorts of 
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patients starting HAART, the prevalence of CMV disease in Mumbai, India, was 11.4%, 
significantly higher than in Cape Town, South Africa, where the prevalence was 2.6% 
(184). A study from Tanzania also found a low prevalence of CMV retinitis (1.3%) in 
patients with CD4+ T cell counts <100 cells/mm3 (185).  
The cause of the low prevalence or CMV retinitis in Africa is unknown, but genetic 
differences in the host or virus could be part of the explanation. A Canadian study found 
that some human leukocyte antigen (HLA) types were associated with increased risk of 
CMV retinitis, i.e. HLA-Bw4 and HLA-DRB115, whereas HLA-Cw7 was protective 
(186). Therefore, it is possible that Africans may have favourable genotypes. However, 
this explanation is challenged by a study from the US that found that the prevalence of 
CMV retinitis was higher in American-Africans (and Hispanics) than in the general HIV-
infected population (187). In contrast, a study from London found that Africans born in 
sub-Saharan Africa had significantly lower incidence of CMV disease compared to non-
African patients (188). Ben-Smith et al. found lower numbers of naïve T cells, higher 
numbers of antigen-experienced T cells and higher CMV seroprevalence in young 
Malawians compared to age-matched UK individuals, suggesting that immune responses 
in rural African settings may be induced and maintained in a different way than in 
developed countries (20). It is possible that early immune challenge in Africa, by 
unknown mechanisms, could reduce the risk of CMV retinitis in immunosuppressed 
individuals in later life.  
As invasive procedures and histopathological examination of biopsies are unavailable to 
most HIV-infected individuals in developing countries, CMV disease is highly likely to 
be missed when present. Autopsy is also seldom performed, but there are some autopsy 
studies from sub-Saharan Africa (189). CMV disease was the presumed main cause of 
death in 4% of adults both in studies from Kenya and South Africa (190;191). Evidence 
of CMV disease was found in up to 18% in a study of adults and adolescents in Cote 
d'Ivoire, whereas 2% of deaths were ascribed to this condition (192). A necropsy study of 
adults in Botswana found evidence of CMV disease in 15% of HIV-positive patients, but 
CMV was a rare cause of death (193). In children, there is some indication that CMV 
disease may be more common. Autopsy studies of Botswanan children showed that 
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CMV disease was the cause of death in 20% of cases (CMV pneumonitis and 
disseminated disease combined), and was found in 66% of autopsies (194). In a study of 
respiratory infection in HIV-infected children in Zambia, CMV pneumonitis was found 
in 22% of cases, but most of these cases were mild (195). 
To conclude, although we were unable to confirm CMV disease in any of our Tanzanian 
patients, other studies have shown that CMV disease does occur in sub-Saharan Africa. 
However, for unknown reasons CMV disease may be less common there than in HIV-
infected individuals in other parts of the world, including Asian developing countries. 
Further studies are warranted to elucidate these findings. 
5.2.3 Survival of patients with CMV disease 
In Paper I, we found that CMV disease diagnosed alive was associated with increased 
risk of death. During the study period, ganciclovir and foscarnet were available to 
patients for treatment of CMV disease, except for two cases that died during the early 
part of the study period. Foscarnet and ganciclovir have been shown to reduce the 
progression of CMV retinitis and other end-organ disease (121-125). Nevertheless, in our 
paper evidence of CMV disease was found at autopsy in all cases, clearly indicating the 
inadequacy of this therapy alone. Our study did not allow us to study if CMV therapy 
was associated with increased survival, but results from other studies are conflicting. 
Some studies from the pre-HAART era found a survival benefit with treatment of CMV 
disease (177;196;197). A later study by Kempen et al. also found that despite HAART, 
CMV treatment reduced the risk of mortality by 65% in patients with CMV retinitis and 
poor immune-recovery (198). However, other studies have been unable to demonstrate a 
survival benefit with systemic CMV treatment (131;199). 
In Paper I, we did not attempt to report the proportion of deaths in which CMV disease 
was the cause of death. Many patients had multiple opportunistic complications that may 
have contributed, and the role of CMV disease was difficult to discern. However, other 
autopsy-based studies in developing countries have reported CMV disease as cause of 
death in around 10 % (53;55;86;88).  
Discussion 
 
46 
 
5.3 CMV viraemia as predictor of CMV disease and death 
Several studies have shown that detectable CMV viraemia by either qualitative or 
quantitative PCR is a risk factor for occurrence and progression of CMV disease, 
progression of HIV infection, and death. In Paper II, we assessed the performance of 
CMV quantitative PCR in the diagnosis of CMV disease in Norway. In Paper III, we 
studied if presence of CMV viraemia in DBS from antiretroviral naive patients in 
Tanzania was a risk factor for death.  
5.3.1 CMV viraemia as predictor of CMV disease 
Several studies have demonstrated that CMV viraemia is associated with statistically 
significant increased risk of CMV disease in HIV-infected individuals (65;92;96;98-
104;107;109;110;112;115-118). However, in clinical practice this information is not very 
helpful. In the diagnostic work-up of a patient, the clinician needs to know the diagnostic 
sensitivity and specificity, and preferable also the positive and negative predictive values 
of the tests in use - and these are often not reported. In Paper II, we analysed the 
diagnostic sensitivity, specificity, positive and negative predictive values of CMV 
quantitative PCR under different assumptions in a population at high risk of CMV 
disease. Other studies that have addressed these parameters using CMV quantitative PCR 
in various blood compartments (serum, plasma, blood or polymorphonuclear leukocytes) 
are summarised in Table 3. Our study included a higher number of cases with CMV 
disease than any of these, and is unique in having assessed the performance of CMV 
quantitative PCR in a population with available autopsy results.  
We found that a maximum overall diagnostic sensitivity of 51% was attained by defining 
a positive test as detectable viraemia in at least one of two plasma samples obtained 
before a diagnosis of CMV alive or at autopsy. Sensitivity was slightly lower (47%), 
when defining as positive only detectable viraemia in the final plasma sample. This is 
because some cases with previous CMV viraemia did not have detectable viraemia in 
subsequent samples, even though CMV therapy was not given. This has also been 
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demonstrated by others (100;108). Shinkai et al. found that peak plasma CMV viral load 
was detected median 4.1 months before the development of CMV disease (100).  
In our study, the diagnostic sensitivity, based on the last samples before diagnosis, was 
lower than in most other studies, both for all cases combined (47%), cases diagnosed 
alive (44%), and at autopsy (49%). We used a validated test with good analytical 
sensitivity (linear range from 400 copies/ml), the time-interval between the last sample 
and diagnosis was approximately two months, similar to several previous studies, and the 
study population was at high risk of CMV disease. Therefore, differences in the 
analytical performance of the tests, differences in timing of samples in relation to 
diagnosis, and differences in study populations are unlikely to explain our relatively low 
diagnostic sensitivity. One possible explanation for low sensitivity is that close follow-up 
and availability of autopsy results enabled us to diagnose less severe cases with CMV 
disease at a very early stage while CMV replication was low and undetectable, cases that 
might have been missed in other studies. For cases first diagnosed at autopsy, the 
diagnostic sensitivity was higher for cases with multi-organ CMV disease (70%), than in 
cases with single organ disease (24%). This is in support of mild disease as an 
explanation for low diagnostic sensitivity.  
In agreement with other studies, the specificity of our test was high under a wide range of 
definitions of a positive test. A false positive test in relation to presence of CMV disease 
occurred in ≤ 11% of cases. Lower specificity reported in some studies might be 
explained by under-diagnosis of CMV disease, e.g. due to lack of autopsy results.  
In our study population, 42% of the patients developed CMV disease, and this is higher 
than in other studies summarised in Table 3. We found an overall negative predictive 
value of 70%. The high prevalence of CMV disease in our population contributes to the 
relatively low negative predictive value. 
The combination of high diagnostic specificity and high prevalence of CMV disease, 
explains the relatively high positive predictive value (76%) of detectable viraemia in our 
study. The positive predictive value could be further increased by raising the defined 
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viral load threshold for a positive result, or by defining as positive only cases with 
detectable viraemia in two out of two consecutive tests.  
In a study conducted prior to the availability of HAART, Wiselka et al. found a positive 
predictive value of CMV quantitative PCR of only 44% (105). Poor predictive values 
(<50%) were also demonstrated in a study using CMV qualitative PCR (106). The low 
positive predictive values in these studies are due relatively low proportion of patients 
with CMV disease and low diagnostic specificity of the tests.  
A study by Edwards et al. of acutely unwell HIV-1 positive individuals with access to 
HAART, found a positive predictive value of only 10% (119). HAART, may have 
prevented development of manifest CMV disease and contributed to the low diagnostic 
specificity (58%). In that study, only a small proportion (6%) of episodes of illness was 
followed by a diagnosis of CMV disease. Also, as autopsy was not performed, CMV 
disease might have been overlooked, resulting in potential underestimation of the true 
specificity and positive predictive value. However, it is likely that the positive predictive 
value for CMV quantitative PCR is low in HIV-infected individuals on effective 
HAART, or with access to treatment.  
Using plasma, we found that CMV quantitative PCR had clear limitations in the 
diagnosis of CMV disease. Although studies of transplant recipients have found the 
analytical sensitivity to be higher in whole blood than in plasma, this does not necessarily 
mean that better positive predictive value is achieved (200;201).We did not test 
cerebrospinal fluid, but other studies have found high sensitivity and specificity using 
this specimen in patients with CMV neurological disease (111;113;114). 
Studies have shown that foscarnet, ganciclovir, and valganciclovir reduce the risk of 
progression of CMV retinitis and other manifestations of CMV disease (121-125;129). In 
a U.S. study by Wohl et al. in patients with access to HAART, valganciclovir used as 
pre-emptive therapy did not significantly reduce the incidence of CMV disease (132). 
However, the power to detect a difference between groups given valganciclor and 
placebo was low due to few cases of CMV disease.
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In contrast, studies using high-dose valaciclovir in the pre-HAART era when CMV disease 
was more common, showed reduced risk of CMV disease, but not reduced risk of death 
(118;128). In a small study from Italy, Foca et al. found that there was no difference in CD4+ 
T cell count and HIV RNA response 52 weeks after starting HAART in patients with and 
without CMV viraemia at baseline (202). All patients had undetectable CMV viraemia after 
52 weeks, even without specific CMV therapy. These results suggest that the risk of CMV 
disease occurring in patients with CMV viraemia and access to HAART in developed 
countries today is considerably lower than reported by us in Paper II. 
In resource-poor countries, access to histopathological examination of tissue is often limited, 
as is availability of advanced microbiological assays such as PCR and other NATs. Therefore, 
the performance of CMV quantitative PCR in diagnosis of CMV disease in this setting is 
unknown. 
5.3.2 CMV viraemia as predictor of death 
In Paper III, we report that 22.6% of antiretroviral naïve patient in Tanzania had detectable 
viraemia at baseline, and 8.3% had CMV viral load >200 copies/ml. CMV viraemia >200 
copies/ml was a significant risk factor for death in multivariable analysis, with a hazard ratio 
of 5.0. Only two previous studies from developing countries have assessed CMV viraemia as 
a risk factor for death, and both found that high CMV viral load was an independent predictor 
(154;203). To our knowledge, our paper is the first to demonstrate that a high CMV viral load 
is an independent risk factor for death in patients with HIV infection in Africa after wide-
scale implementation of HAART. 
Studies from developed countries in the pre-HAART era found that CMV viraemia was 
associated both with the development of CMV disease and death (104;116;152). Although the 
incidence of CMV disease in patients with HIV has been considerably reduced in patients 
with access to HAART, several studies have shown that CMV viraemia continues to represent 
a risk factor for death (73;109;110;115;151). Darwich et al. reported that HIV-infected 
patients with high specific interferon-gamma responses to CMV had better prognosis than 
patients with lower responses (204).  
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As CMV viraemia has been associated with poor prognosis in patients both before and after 
the introduction of HAART, a natural question to ask is if pre-emptive treatment of CMV can 
improve prognosis. No such studies have been conducted in developing countries, but Wohl et 
al. found no significant benefit on survival by the use of valganciclovir in a population with 
CMV viraemia, access to HAART and low incidence of CMV disease (132). Hunt et al. found 
that valganciclovir reduced immune activation in HIV-infected patients with low CD4+ T cell 
counts, but did not observe a significant increase in CD4+ T cell counts during a relatively 
short observation period (166). Present guidelines for the prevention and treatment of 
opportunistic infections in HIV-infected adolescent do not recommend CMV treatment for 
patients with asymptomatic CMV viraemia (89).  
Previous studies from Australia and Europe have demonstrated a survival benefit with the 
administration of high-dose aciclovir to HIV-infected individuals, but have not found that 
aciclovir reduces the incidence of CMV disease (205;206). Studies from Africa have 
demonstrated that aciclovir treatment of HSV-2 in antiretroviral naïve HIV-infected patients 
is associated with a survival benefit (207;208). This effect may result from direct 
antiretroviral effect of aciclovir on HSV-2, but may also be mediated by a reduction in HSV-
2-induced immune activation. In addition, a CMV-mediated effect on survival cannot be 
excluded. Valganciclovir is more active against CMV than aciclovir, and studies of the effect 
of this drug should therefore be considered in individuals with CMV viraemia in developing 
countries. 
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6 Conclusions and future perspectives 
6.1 Conclusions 
This thesis shows that CMV infection, CMV viraemia and CMV disease have serious 
consequences for HIV-infected individuals. Several challenges remain in the diagnosis and 
treatment of CMV disease, both in developed and developing countries. 
I. Incidence of CMV disease in patients with AIDS in the pre-HAART era 
Prior to the availability of HAART, CMV disease occurred frequently in patients with HIV 
infection in Oslo, and was diagnosed in almost one half of the patients at autopsy. More than 
two-thirds of these cases were undiagnosed prior to death. CMV infection was significantly 
more frequent in MSM than in IDUs. Retinitis was the most common manifestation.  
II.  Impact of CMV seropositivity and end-organ disease on survival in patients with 
AIDS in the pre-HAART era 
There was no significant difference in survival between CMV seropositive and seronegative 
individuals. CMV disease diagnosed alive was associated with increased risk of death. 
Despite CMV therapy, there was evidence of CMV disease at autopsy in all patients, clearly 
demonstrating the inadequacy of CMV treatment alone. 
III.  Utility of plasma CMV quantitative PCR in the diagnosis of CMV disease in 
patients with HIV-infection  
CMV viraemia was more common in patients with CMV disease than in patients without 
CMV disease. The test only correctly identified one half of all patients with CMV disease, but 
more than two-thirds of patients with multi-organ disease. Few patients had CMV viraemia in 
the absence of CMV disease. Patients with high CMV viral load, or detectable viral load in 
more than one sample, were highly likely to have CMV disease, but by applying such 
stringent criteria many cases of CMV disease would be missed. CMV quantitative PCR is a 
valuable adjunct to diagnosis of CMV disease, but is far from perfect in discriminating 
between individuals with and without CMV disease. 
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IV. Utility of DBS for detection of CMV antibody and CMV viraemia in HIV-
infected individuals in a resource-poor setting 
We found that DBS are suitable for detection of CMV antibody and viraemia in a resource-
poor area. CMV viral load in DBS tended to underestimate plasma viral load, but this may not 
be of great clinical significance. 
V. Prevalence of CMV infection and viraemia in relation to clinical outcome in 
patients with HIV infection and access to HAART in rural Tanzania 
All antiretroviral naïve HIV-infected patients in the rural study area of Tanzania were CMV 
seropositive. Detectable CMV viraemia was common, and presence of viral load >200 
copies/ml in DBS eluates was a significant risk factor for death, despite availability of 
HAART. Many patients had low CD4+ T cell counts and were at risk of CMV disease. A 
subgroup of these patients also had high CMV viral load and symptoms compatible with 
CMV disease. Although no cases were diagnosed with confirmed CMV disease, this may be 
due to diagnostic constraints.  
6.2 Future perspectives of HIV-associated CMV morbidity in the 
HAART era 
Currently, CMV disease represents a relatively small threat to HIV-infected patients with 
access to HAART. However, even in these populations, CMV disease will continue to occur 
in individuals first diagnosed after the development of severe immunodeficiency, and in 
patients with suboptimal treatment response due to poor treatment adherence or viral 
resistance. To prevent this serious opportunistic disease, priority should be given to early 
diagnosis of HIV-infection and timely administration of HAART. At the same time, clinicians 
need to be vigilant to symptoms of CMV disease and CMV immune recovery uveitis in HIV-
infected patients at risk.  
CMV disease remains a difficult diagnosis to make, and there is a clear need for future studies 
aiming to improve diagnosis of CMV disease. For this purpose a multifaceted approach is 
warranted, using information from patient history and clinical examination, in addition to 
results of immunological, microbiological, radiological, and histopathological tests. However, 
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as CMV disease has become a rare disease in populations with access to HAART, such 
studies will be hard to perform. CMV disease is therefore likely to be a challenging diagnosis 
to make in HIV-infected individuals for many years to come.  
Analysis of CMV viraemia in DBS has several potential advantages compared to liquid 
samples, and DBS are particularly suitable for use in developing countries. However, there 
remain methodological challenges that have not yet been fully solved. Further validation of 
CMV quantitative PCR in DBS is needed before DBS can replace plasma samples in routine 
practice.  
In developing countries, there is a need for further studies on the impact of CMV infection, 
viraemia and disease, including the role of CMV in accelerating the progression of HIV 
disease. Trials are needed to assess if diagnosis and treatment of CMV disease and viraemia 
can improve prognosis for patients in this part of the world. 
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Abstract
Background: Patients with advanced HIV infection at the time of diagnosis and patients not
responding to antiretroviral therapy are at risk of cytomegalovirus (CMV) disease. Earlier studies
of patients with HIV infection have demonstrated that the diagnosis is often first made post-
mortem. In recent years new molecular biological tests have become available for diagnosis of CMV
disease. Although clinical evaluation of tests for diagnosis of CMV disease in HIV-infected individuals
is suboptimal without autopsy, no results from such studies have been published. The aim of this
study was to explore the diagnostic utility of CMV quantitative polymerase chain reaction (PCR) in
plasma from HIV and CMV seropositive patients who died during the period 1991–2002 and in
whom autopsy was performed.
Methods: Autopsy was performed in all cases, as part of routine evaluation of HIV-infected cases
followed at Ullevaal University Hospital. Of 125 patients included, 53 had CMV disease, 37 of whom
were first diagnosed at autopsy. CMV disease was diagnosed either by ophthalmoscopic findings
typical of CMV retinitis, biopsy or autopsy. One or two plasma samples taken prior to the first
diagnosis of CMV disease (alive or at autopsy) or death without CMV disease were analysed by
CMV quantitative PCR. Sensitivity, specificity, positive and negative predictive values were
calculated for different CMV viral load cut-offs and according to detection of viraemia in one versus
two samples.
Results: Twenty-seven of 53 patients with CMV disease (51%) and 10 of 72 patients without CMV
disease (14%) had detectable viraemia in at least one sample. Sensitivity and negative predictive
value (NPV) of the test, maximised with a cut-off at the test's limit of detection of CMV viraemia
(400 copies/mL), were 47% and 70%, respectively. With cut-off at 10 000 copies/mL, specificity and
positive predictive value (PPV) were 100%. With a requirement for CMV viraemia in two samples,
specificity and PPV were 100% in patients with CMV viraemia above the limit of detection.
Conclusion: Our results indicate that quantitative CMV PCR is best used to rule in, rather than
to rule out CMV disease in HIV-infected individuals at high risk.
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Background
Although the incidence of cytomegalovirus (CMV) disease
in HIV-infected patients has declined sharply after the
introduction of highly active antiretroviral therapy
(HAART) [1], many patients are still at risk of CMV disease
[2,3]. Clinical features associated with CMV disease are,
with the exception of CMV retinitis, unspecific. In cases
with extra-ocular disease, histopathological findings typi-
cal of CMV are required for verification of the diagnosis.
Earlier studies, not using modern molecular biological
methods for CMV disease, demonstrated that CMV dis-
ease was under-diagnosed in HIV-infected patients, and
that the diagnosis was often first made at autopsy [4-10].
Newer diagnostic tests may improve the detection rate of
CMV disease in this patient population. French guidelines
recommend both ophthalmocsopy and testing for CMV
viraemia by PCR every three months in patients with CD
4 cell counts below 50–100/mm3, whereas U.S. guidelines
focus on the early clinical recognition of CMV disease
[11,12].
A variety of microbiological tests for detection of CMV
DNA in blood [3,13-27] and cerebrospinal fluid [28] have
been used in the diagnosis of CMV disease. Previous stud-
ies have demonstrated that detection of CMV DNA in
blood by PCR is a risk factor for subsequent development
of CMV disease. Sensitivity, specificity, positive and nega-
tive predictive value of these tests have shown great varia-
tion [13,18-20,23,26,27]. In one recent study, plasma
CMV viraemia was not found to be associated with later
development of CMV disease, but was predictive of death
[29].
Because diagnosis of CMV disease is often first made at
autopsy, sensitivity and negative predictive value of diag-
nostic tests may be overestimated, and specificity and pos-
itive predictive value may be underestimated if autopsy
results are not available. Furthermore, by using a quanti-
tative method it may be possible to improve specificity
and positive predictive value of CMV detection. However,
to our knowledge, no previous studies have related the
results of CMV quantitative PCR to autopsy findings. The
objective of this study was to explore the diagnostic utility
of CMV quantitative PCR in plasma samples from a group
of HIV infected patients who died during the study period
and in whom autopsy was performed.
Methods
Patients included in this retrospective study were HIV and
CMV seropositive adolescents and adults who died during
the period 1991–2002 while they were followed up at Ull-
evaal University Hospital. A total of 125 patients were
included. Patients were generally not screened for CMV
disease, even with low CD 4 cell counts, but fundoscopy
or biopsy of relevant organs was performed on the basis
of suggestive clinical signs and symptoms. Autopsy was
performed in all cases as part of routine practice in the
evaluation of HIV-infected cases who died at Ullevaal
University Hospital, unless this was objected to by rela-
tives. Patient characteristics are shown in Table 1.
A full autopsy including neuropathological examination
was performed in every case. Paraffin-embedded sections
were routinely stained with haematoxylin-eosin (HE),
and confirmatory immunohistochemistry for CMV was
performed in cases where microscopy of HE stained biop-
sies were inconclusive. CMV disease was verified by dem-
onstration of characteristic cytomegalocytes with
inclusions in histopathological samples by light micros-
copy. However, ante-mortem diagnosis of CMV retinitis
was defined as typical ophthalmoscopic findings in
patients examined by an experienced ophthalmologist.
Among 53 patients diagnosed with CMV disease, sixteen
patients were first diagnosed before death. Of patients
diagnosed alive, twelve had retinitis and four had biopsy
verified gastrointestinal infection (colitis 2, oesophagitis
1, stomatitis 1) as their first end-organ manifestation of
CMV disease. Except for two patients diagnosed with
retinitis alive, all had CMV disease confirmed in one or
several organs at autopsy. Thirty-seven cases were first
diagnosed at autopsy. In these patients the number of
CMV end-organ manifestations at autopsy were: adrenali-
tis 26, pneumonitis 22, encephalitis 16, retinitis 14, gas-
trointestinal infection 14 (oesphagitis 11, gastritis 1, small
intestine infection 1, colitis 1), and other end-organ dis-
ease 11 (prostate gland 5, ovaries 2, uterus 1, epididymis
1, lymph node 2, pancreas 5, spleen 3, liver 3, kidney 4,
myocardium 1, thyroid gland 4, vascular endothelium 1).
Twenty-patients first diagnosed at autopsy had more than
one organ manifestations of CMV disease.
Only twenty-eight patients received HAART at the time of
the last plasma sample tested for CMV DNA, either before
the first diagnosis of CMV disease (alive or at autopsy), or
before death in patients never developing CMV disease.
This is because the majority of plasma samples were taken
prior to the introduction of HAART in 1996. Seven cases
with CMV disease (diagnosed 1997–2002) were on
HAART when the last plasma sample was taken and later
analysed with CMV PCR. However, HIV viral load was
high in all, ranging from 17000 – >750 000 copies/mL.
Two of these seven cases had CMV retinitis diagnosed
alive, whereas the remaining five were first diagnosed with
CMV at autopsy.
Plasma aliquots were routinely collected and stored at -
20°C or colder during the study period, as part of clinical
follow-up of patients. From cases with CMV disease, the
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last one or two (according to availability) plasma samples
prior to diagnosis were retrospectively analysed by quan-
titative CMV PCR. In patients with more than one CMV
diagnosis at different time points during life or at autopsy,
plasma samples taken prior to the first CMV diagnosis
were tested. Similarly, for patients without CMV disease,
the last one or two plasma samples before death were
tested. The samples were analysed by COBAS AMPLICOR
CMV Monitor test (Roche Molecular System, Branchburg,
NJ) according to the manufacturer's recommendations.
One low-positive control, one high-positive control, and
one CMV-negative control were processed with each batch
of samples. The linear range of this assay is between 400
and 100 000 CMV DNA copies/mL plasma.
A total of 82 plasma samples were tested before diagnosis
in patients with CMV disease, and 127 samples were ana-
lysed from patients without CMV disease. Median time
interval between the last plasma sample and the date of
the first (or only) CMV diagnosis (alive or post-mortem)
was 69 days. Median time interval between the last
plasma sample and date of death in patients not develop-
ing CMV disease at any time was 79 days. This difference
was not statistically significant. For patients first diag-
nosed alive with CMV disease, the median time interval
between the last sample and diagnosis was 64 days, as
compared to 70 days for patients first diagnosed at
autopsy (statistically not significantly different). Among
29 patients with CMV disease and 55 patients without
CMV disease from whom two samples were tested,
median time intervals between the two tests were 77 days
and 90 days, respectively, again not statistically different.
The CMV quantitative PCR results were used to study sen-
sitivity, specificity, PPV and NPV of the test with different
cut-off values for CMV viral load, and with viraemia in
one versus two samples.
CD 4 cell counts were available from electronic records
and had been measured in blood samples taken on the
same day that plasma had been taken for later quantita-
tive CMV PCR.
SPSS statistical software version 13.0 (SPSS Inc. New York,
2004) was used to calculate Spearman rank correlation
between CD4 cell counts and CMV viral load. Statistical
differences between groups were calculated using non-
parametric tests (Mann-Whitney and chi-square test as
Table 1: Characteristics of 125 patients included in the study
Characteristic Value
CMV disease Without CMV disease
N = 53 (%) N = 72 (%)
Risk category
Men who have sex with men 32/53 (60) 30/72 (42)
Intravenous drug user 9/53 (17) 30/72 (42)
Other 10/53 (19) 11/72 (15)
Unknown 2/53 (4) 1/72 (1)
Age (median) at time of death, years 39 41
Sex
Male 46/53 (87) 58/72 (81)
Female 7/53 (13) 14/72 (19)
CD4 cell count*
Median count, cells/mm3 17 69
<100 cells/mm3 47/53 (89) 41/72 (57)
<50 cells/mm3 43/53 (81) 32/72 (44)
Highly active antiretroviral therapy* 7/53 (13) 21/72 (29)
Plasma HIV RNA level*
Tested 10/53 (19) 35/72 (49)
Median among tested, copies/mL blood 305 000 35 000
HIV RNA < 400 copies/mL blood 0/10 (0) 10/35 (29)
HIV RNA < 50 copies/mL blood 0/10 (0) 5/35 (14)
Data shown are number of subjects per no. of subjects with available data
* at time of last sample prior to diagnosis of CMV disease or death without CMV disease
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appropriate). Logistic regression was performed using
presence or absence of CMV disease as dependent variable
and last CD4 cell count (above or below 100/mm3, last
CMV viral load (log transformed), HAART (yes or no),
time in days between last plasma sample or outcome
defined as CMV disease or death without CMV disease,
sex, and age at time of death as independent variables.
Confidence Interval Analysis statistical software (Wilson's
method) was used to calculate sensitivity, specificity, PPV
and NPV with confidence intervals. All confidence inter-
vals (CI) are 95% CIs. The significance level was set at 5%.
Results
Twenty-seven of 53 patients with CMV disease (51%) and
10 of 72 patients without CMV disease (13%) had detect-
able viraemia in at least one sample (p < 0.001). Results
of CMV quantitative PCR from the last plasma sample are
shown in Table 2. There was significantly higher CMV
viral load in patients with CMV disease compared to
patients without CMV disease (p < 0.001). In 25 patients
with CMV disease and 8 patients without CMV disease
who had viraemia in the last sample, median CMV viral
loads were 3420 (range 392–261 000) and 1705 (range
277–9620) DNA copies/mL, respectively (statistically not
significantly different). Table 2 also shows the number of
cases with detectable CMV viraemia according to the
number of samples tested.
Among 16 patients diagnosed alive with CMV disease, 7
(44%) had detectable CMV viraemia in the last sample
before diagnosis (median 1810 DNA copies/mL among
viraemic cases). Among 37 patients first diagnosed with
CMV disease at autopsy, 18 (49%) had CMV viraemia in
the last sample (median 4430 DNA copies/mL among
viraemic cases). There was no significant difference in the
proportion of cases with viraemia (sensitivity) or level of
viraemia between these two groups of patients.
In 37 patients first diagnosed with CMV disease at
autopsy, 14 of 20 patients with CMV disease in more than
one organ had detectable CMV viremia in the last sample
(median 7035 copies/mL among viraemic cases), com-
pared to 4 of 17 patients with CMV disease in a single
organ, (median 2680 DNA copies/mL among viraemic
cases). In other words, sensitivity of the test was 70% for
cases with multi-organ disease and 24% for cases with sin-
gle organ disease (p = 0.005). However, among viraemic
cases there was no statistically significant difference in
CMV viral load.
Results from Table 2 were used to calculate the corre-
sponding sensitivity, specificity, PPV and NPV with
increasing CMV viral load cut-off, and with one or two
samples with detectable viraemia in individual patients
(Table 3). The viral load cut-off is defined as the lowest
level of viraemia which is considered a positive result for
diagnostic purposes. Sensitivity and NPV were generally
low under a wide range of assumptions. Specificity and
PPV were generally higher, and were improved further by
raising the viral load cut-off. By setting the cut-off at 10
000 CMV DNA copies/mL plasma, a specificity of 100%
was attained, but at the expense of sensitivity which fell to
17%. Also, a specificity and PPV of 100% was achieved by
defining a positive test as CMV viraemia in two samples.
The proportion of cases with CMV disease that have a pos-
itive tests (sensitivity) plotted against the proportion of
cases without CMV disease that have a positive test (1-spe-
cificity) for all measured values of CMV DNA viraemia in
the last plasma sample are shown as a receiver operating
characteristic (ROC) curve in Figure 1. Using the lowest
detectable level of viraemia as cut-off, a maximum sensi-
tivity of 47.2% was attained. However, specificity of 1
(100%) (1-specifity = 0) was attained with a cut-off of 10
000 CMV DNA copies/mL as mentioned above. The diag-
nostic accuracy of the test, expressed by the area under the
curve, was 0.69. This area corresponds to the probability
that a random person with the disease has a higher CMV
viral load than a random person without CMV disease.
CMV viraemia was negatively correlated with CD4 cell
counts (rS = -0.24 (p < 0.01). In the multivariable logistic
regression model low CD4 cell counts and high CMV viral
load were the only statistically significant positive predic-
tors of CMV disease.
Discussion
With the exception of retinitis, end-organ manifestations
of CMV disease in HIV-infected individuals have unspe-
cific clinical characteristics, and histopathological confir-
mation is required for definite diagnosis. Because biopsy
of affected organs may be difficult to obtain, there is a
need for microbiological diagnostic methods that can be
used on readily available specimens. A variety of tests to
detect CMV nucleic acids have been evaluated in different
patient populations. To our knowledge, no previous tests
have been evaluated in relation to autopsy findings, an
important shortcoming, as histological verification of
CMV disease is often first obtained at autopsy. The main
strength of this study is that it explores the utility of quan-
titative PCR in the diagnosis of CMV disease in HIV-
infected individuals with available autopsy results. Also, it
includes one of the highest reported number of cases of
CMV disease in HIV-infected patients evaluated with CMV
PCR.
Several qualitative and quantitative PCR methods for
CMV in plasma in various patient populations have dem-
onstrated sensitivity in the range 35–93% [13,18-
20,23,26,27]. In our study, maximum sensitivity of 47%
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for the total number of cases, using a cut-off at the limit of
detection, was in the lower end of this range. In a small
previous study on HIV-infected individuals using COBAS
AMPLICOR CMV Monitor, sensitivity was 92% [27]. The
relatively low sensitivity in our study could be due to sam-
ples in many cases having been taken as part of routine
monitoring and therefore too long, a median of 69 days,
before development of CMV end-organ disease. However,
CMV viraemia is known to often precede development of
CMV disease by several months [2,13,17]. Also, in con-
trast to previous studies, most of our cases of CMV disease
were first diagnosed at autopsy, and it is possible that
these post-mortem manifestations are associated with a
shorter time with viraemia and/or lower level of viraemia.
Interestingly, our results show that sensitivity was signifi-
cantly higher for patients with CMV disease in more than
one organ compared to patients with single organ disease.
Previous studies of CMV disease diagnosed before death
have yielded specificities in the range 47–100% [13,18-
20,23,26,27]. Our study shows specificity in the upper
range (89%), with only 8 of 72 (11%) cases having detect-
able CMV viraemia but no diagnosis of CMV disease (false
positive tests). Studies that do not include autopsy results
may underestimate the specificity, as CMV end-organ dis-
ease may be a difficult clinical diagnose to make.
Our data were also analysed with regard to detection of
CMV viraemia in one versus two plasma samples taken at
different times. We found that cases with detectable CMV
viraemia in both samples all developed CMV disease.
Thus, by requiring confirmation in a second test if the first
was positive, a specificity of 100% was attained, but at the
cost of lower sensitivity.
From a clinician's point of view, the predictive value of a
positive and negative test result has greater practical impli-
cations than do sensitivity and specificity. The predictive
value of any test is generally dependent on the prevalence
of the disease in question in the study population, NPV
decreasing and PPV increasing with increasing prevalence.
Previous studies have reported NPV in the range 80–95%
[20,23,26,27], which is somewhat higher than in our
study. The prevalence of CMV disease in our study was
comparatively high – 42% (53 of 125 patients) – thus
contributing to a low NPV. For the same reason, the PPV
demonstrated in our study was among the highest
reported. In our patient population at high risk of CMV
disease we attained a PPV of 100% with a cut off-value of
10 000 CMV DNA copies/mL or a requirement for virae-
mia in two consecutive tests. Studies that do not include
autopsy results may underestimate the proportion of cases
with CMV disease, resulting in an overestimation of the
NPV and an underestimation of the PPV.
The study covers a period both before and after HAART
became standard of care. Even in patients on HAART,
antiretroviral treatment was suboptimal for many, proba-
bly due to HIV resistance having developed after previous
ineffective therapy with single drugs, or combination of
two antiretrovirals. This may affect the external validity of
our results in the diagnosis of CMV disease in HIV-
Table 2: Results of CMV quantitative PCR in patients with and without CMV disease
Results of CMV PCR assay Number of patients
with CMV disease without CMV disease
N = 53 N = 72
Viral load (CMV DNA copies/mL) (last samples)
Below limit of detection 28 64
Viraemiaa 25 8
d1 999 9 5
2 000–9 999 7 3
t10 000 9 0
CMV DNA detectiona by no. of tested samples before diagnosis
One sample 24 17
Not detected in any sample 13 15
Detected in one sample 11 2
Two samples 29 55
Not detected in any sample 13 47
Detected in one sample 9 8
Detected in both samples 7 0
aAny viraemia above limit of detection.
Results of plasma CMV quantitative PCR in HIV patients with and without CMV disease by different viral load cut-offs and number of tested 
samples.
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infected patients who have access to more effective
HAART today and, as a result, have lower risk of CMV dis-
ease. However, results from our study are likely to be rele-
vant for patients who interrupt treatment, who fail to
respond to antiretroviral therapy, or who are diagnosed
too late for effective HIV therapy to be initiated.
This was a retrospective study in which the time intervals
varied considerably between the last plasma sample and
CMV diagnosis (alive or at autopsy), or between the last
plasma sample and death in cases without CMV disease,
as samples were taken as part of routine monitoring of the
patients rather than on clinical suspicion. It is likely that
the sensitivity and PPV of CMV PCR will be higher in a set-
ting where plasma is analysed at a time of clinical suspi-
cion of CMV end-organ disease, rather than as part of
routine monitoring of patients.
The availability of more than one plasma sample from
individual patients at relevant time points was limited,
but a high positive predictive value for CMV disease was
found for patients with CMV viraemia in two consecutive
tests with a median time interval of between two and three
months. However, our data do not allow us to conclude
when plasma CMV quantitative PCR should be per-
formed, or how soon a patient should be retested after a
positive test result.
In solid organ transplant patients and allogenic bone mar-
row transplantation, routine monitoring of virological
markers for cytomegalovirus and administration of pre-
emptive therapy has been shown to significantly reduce
the risk of CMV disease [30,31], and post-transplant mon-
itoring of CMV viraemia by PCR or other methods is used
in many centres. Among HIV-infected individuals the
value of pre-emptive therapy is less well documented, but
monitoring of high risk patients for this purpose is recom-
mended in French guidelines [11].
Many studies have shown that the risk of CMV disease
sharply increases when CD4 cell counts fall below 100/
mm3 [2,3,32]. We suggest that HIV infected patients with
low CD4 cell counts who have clinical features suggestive
of CMV disease, should have plasma tested for CMV by
quantitative PCR as part of the diagnostic procedure. In
patients with repeated viraemia or viraemia above 10 000
CMV DNA copies/mL, pre-emptive therapy should be
considered after a careful clinical examination for signs
and symptoms of CMV end-organ disease. However, our
findings need to be validated in prospective studies on
patients living with HIV today.
Conclusion
Using CMV quantitative PCR, the sensitivity and NPV for
CMV disease were low in this study. Our results indicate
that in a population at high risk of CMV disease quantita-
tive CMV PCR is best used to rule in, rather than to rule
out CMV disease. Although CMV disease presently is rela-
tively uncommon in HIV-infected patients who have
access to antiretroviral therapy, these results may have
implications for diagnosis of CMV disease in patients with
low CD4 cell counts due to late HIV diagnosis or failure of
antiretroviral therapy.
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